These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15585987)

  • 1. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention.
    Aggarwal A; Blum A; Schneider DJ; Sobel BE; Dauerman HL
    Coron Artery Dis; 2004 Dec; 15(8):471-5. PubMed ID: 15585987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Furman MI; Krueger LA; Linden MD; Fox ML; Ball SP; Barnard MR; Frelinger AL; Michelson AD
    J Thromb Haemost; 2005 Feb; 3(2):312-20. PubMed ID: 15670038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention.
    Welt FG; Rogers SD; Zhang X; Ehlers R; Chen Z; Nannizzi-Alaimo L; Phillips DR; Simon DI
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):185-9. PubMed ID: 14755809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting.
    Aggarwal A; Schneider DJ; Sobel BE; Dauerman HL
    Am J Cardiol; 2003 Oct; 92(8):924-9. PubMed ID: 14556867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.
    Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
    Coron Artery Dis; 2005 Sep; 16(6):401-5. PubMed ID: 16118546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
    J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.
    Schweiger MJ; Changezi HU; Naglieri-Prescod D; Cook JR
    Clin Ther; 2003 Jan; 25(1):225-34. PubMed ID: 12637122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response.
    Aggarwal A; Schneider DJ; Terrien EF; Gilbert KE; Dauerman HL
    J Thromb Thrombolysis; 2003 Feb; 15(1):25-31. PubMed ID: 14574073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
    Lincoff AM; Kereiakes DJ; Mascelli MA; Deckelbaum LI; Barnathan ES; Patel KK; Frederick B; Nakada MT; Topol EJ
    Circulation; 2001 Jul; 104(2):163-7. PubMed ID: 11447080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
    Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
    Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).
    Kirtane AJ; Parise H; Mehran R; Moses JW; Fahy M; Bertrand ME; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Ware JH; Pocock SJ; Lansky AJ; Stone GW
    Am J Cardiol; 2010 Jul; 106(2):180-6. PubMed ID: 20599000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting.
    Yip HK; Wu CJ; Yang CH; Chang HW; Fang CY; Hung WC; Hang CL
    Circ J; 2005 Aug; 69(8):890-5. PubMed ID: 16041155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.